Pfizer reported a quarterly loss Tuesday on a lot decrease gross sales of Covid-19 merchandise because it emphasised progress on cost-cutting and drug improvement initiatives.
The massive US pharma firm, which has been credited with important Covid-19 vaccines and Paxlovid therapeutic, described itself as on monitor with a transition to a post-pandemic surroundings that features a heavy emphasis on new oncology merchandise.
ALSO READ: ‘F**okay Pfizer…the reality is coming’: Amanda Black tweets anti-vax rant
Pfizer
“We’re inspired by the robust efficiency of our non-COVID merchandise within the fourth quarter of 2023, together with vital contributions from new launches and sturdy year-over-year development for a number of key in-line manufacturers,” mentioned Chef Government Albert Bourla.
The drugmaker misplaced $3.4 billion within the fourth quarter, in contrast with earnings of $5.0 billion within the year-ago interval.
ALSO READ: Over 8m Pfizer vaccine doses will expire on the finish of October
Revenues fell 41 p.c to $14.2 billion on account of a lot decrease Covid-19 associated gross sales.
Pfizer reiterated its 2024 income forecast of $58.5-$61.5 billion after 2023 revenues got here in at $58.5 billion.
ALSO READ: ‘Why is Shona in it?’: Bantu Holomisa dragged over Pfizer vaccine tweet
The corporate mentioned it’s on monitor with efforts to ship at the very least $4 billion in annual price financial savings by the top of 2024.
Nevertheless, Pfizer mentioned its 2024 outcomes might be lowered by 40 cents per share in financing prices stemming from its acquisition of Seagen in December, which strengthens Pfizer’s oncology enterprise.
Bourla
Bourla mentioned Pfizer expects 2024 launches of latest merchandise for superior/metastatic bladder most cancers and prostate most cancers.
ALSO READ: Alopecia drug push? Oscars co-sponsor Pfizer slams ‘staged slap’ concept
The corporate plans an “Oncology Innovation Day” on February 29.
Shares of Pfizer rose 0.3 p.c in pre-market buying and selling.
© Agence France-Presse
